Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas

We investigated a therapeutic strategy for recurrent malignant gliomas using mesenchymal stem cells (MSC), expressing cytosine deaminase (CD), and prodrug 5-Fluorocytosine (5-FC) as a more specific and less toxic option. MSCs are emerging as a novel cell therapeutic agent with a cancer-targeting pro...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Theranostics
Autori principali: Chung, Taemoon, Na, Juri, Kim, Young-il, Chang, Da-Young, Kim, Young Il, Kim, Hyeonjin, Moon, Ho Eun, Kang, Keon Wook, Lee, Dong Soo, Chung, June-Key, Kim, Sung-Soo, Suh-Kim, Haeyoung, Paek, Sun Ha, Youn, Hyewon
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ivyspring International Publisher 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4955049/
https://ncbi.nlm.nih.gov/pubmed/27446484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.14158
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi